CO2023012342A2 - Inhibidores de enzimas - Google Patents

Inhibidores de enzimas

Info

Publication number
CO2023012342A2
CO2023012342A2 CONC2023/0012342A CO2023012342A CO2023012342A2 CO 2023012342 A2 CO2023012342 A2 CO 2023012342A2 CO 2023012342 A CO2023012342 A CO 2023012342A CO 2023012342 A2 CO2023012342 A2 CO 2023012342A2
Authority
CO
Colombia
Prior art keywords
enzyme inhibitors
compounds
formula
medicine
compositions
Prior art date
Application number
CONC2023/0012342A
Other languages
English (en)
Inventor
Hannah Joy Edwards
Rebecca Louise Davie
Sally Louise Marsh
David Philip Rooker
William Jack Greves
Carl Leslie North
Alicja Stela Obara
David Edward Clark
Christophe Fromont
Jake Simon Peat
Stephen John Pethen
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2102384.1A external-priority patent/GB202102384D0/en
Priority claimed from GBGB2104788.1A external-priority patent/GB202104788D0/en
Priority claimed from GBGB2106284.9A external-priority patent/GB202106284D0/en
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CO2023012342A2 publication Critical patent/CO2023012342A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I): Fórmula (I) composiciones que comprenden tales compuestos; el uso de tales compuestos en medicina; y métodos para tratar pacientes con tales compuestos; en donde A, W, V, Z, U, X, Y y B están definidos en la presente.
CONC2023/0012342A 2021-02-19 2023-09-18 Inhibidores de enzimas CO2023012342A2 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163151178P 2021-02-19 2021-02-19
GBGB2102384.1A GB202102384D0 (en) 2021-02-19 2021-02-19 Enzyme inhibitors
US202163169607P 2021-04-01 2021-04-01
GBGB2104788.1A GB202104788D0 (en) 2021-04-01 2021-04-01 Enzyme inhibitors
US202163182283P 2021-04-30 2021-04-30
GBGB2106284.9A GB202106284D0 (en) 2021-04-30 2021-04-30 Enzyme inhibitors
PCT/GB2022/050447 WO2022175675A1 (en) 2021-02-19 2022-02-18 Factor xiia inhibitors

Publications (1)

Publication Number Publication Date
CO2023012342A2 true CO2023012342A2 (es) 2023-09-29

Family

ID=80595374

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0012342A CO2023012342A2 (es) 2021-02-19 2023-09-18 Inhibidores de enzimas

Country Status (12)

Country Link
EP (1) EP4294798A1 (es)
JP (1) JP2024507222A (es)
KR (1) KR20230157981A (es)
AU (1) AU2022222458A1 (es)
BR (1) BR112023016539A2 (es)
CA (1) CA3211159A1 (es)
CL (1) CL2023002446A1 (es)
CO (1) CO2023012342A2 (es)
IL (1) IL305307A (es)
MX (1) MX2023009677A (es)
TW (1) TW202302565A (es)
WO (1) WO2022175675A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038282A1 (en) * 2022-08-18 2024-02-22 Kalvista Pharmaceuticals Limited 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2683397T3 (pl) 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
HUE041544T2 (hu) * 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
WO2015199206A1 (ja) * 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
MA41253A (fr) * 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
AR108326A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN109475530B (zh) 2016-05-23 2022-03-01 洛克菲勒大学 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂
US11014920B2 (en) 2016-11-18 2021-05-25 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
EP3541375B1 (en) 2016-11-18 2023-08-23 Merck Sharp & Dohme LLC Factor xiia inhibitors
CA3063934A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
US11312723B2 (en) 2017-11-29 2022-04-26 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases
CA3083624A1 (en) * 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-mll interaction
GB201805174D0 (en) 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
WO2019241131A1 (en) * 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
BR112021005914A2 (pt) * 2018-10-01 2021-06-29 Genzyme Corporation derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso
EP3939979A4 (en) * 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd KINASE JAK INHIBITOR, METHOD FOR PREPARING IT AND ITS APPLICATIONS IN THE FIELD OF MEDICINE
CN112174951A (zh) * 2019-07-02 2021-01-05 深圳美莹基因科技有限公司 作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物
WO2021022178A1 (en) * 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
US20220306640A1 (en) * 2019-09-06 2022-09-29 Ono Pharmaceutical Co., Ltd. Hydantoin derivative
EP4034530A4 (en) * 2019-09-27 2023-09-06 Board of Regents, The University of Texas System PROTEIN KINASE I INHIBITORS INTERACTING WITH RECEPTORS FOR THE TREATMENT OF DISEASE
EP4211132A1 (en) * 2020-09-08 2023-07-19 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof

Also Published As

Publication number Publication date
CA3211159A1 (en) 2022-08-25
CL2023002446A1 (es) 2024-01-12
TW202302565A (zh) 2023-01-16
AU2022222458A1 (en) 2023-08-24
MX2023009677A (es) 2023-08-25
WO2022175675A1 (en) 2022-08-25
JP2024507222A (ja) 2024-02-16
KR20230157981A (ko) 2023-11-17
IL305307A (en) 2023-10-01
EP4294798A1 (en) 2023-12-27
BR112023016539A2 (pt) 2023-11-14

Similar Documents

Publication Publication Date Title
BR112022011421A2 (pt) Inibidores da proteína mutante kras
ECSP22012826A (es) Inhibidores de parp1
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2022000481A2 (es) Inhibidores de enzimas
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
CO2022000270A2 (es) Inhibidores de enzimas
CL2022002695A1 (es) Inhibidores de rip1k
CO2023012342A2 (es) Inhibidores de enzimas
CL2021000328A1 (es) Inhibidores de transglutaminasa 2 (tg2)
CO2022000266A2 (es) Inhibidores de enzimas
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
CO2022000422A2 (es) Inhibidores de enzimas
CL2022000214A1 (es) Inhibidores de enzimas
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
CL2022003812A1 (es) Inhibidores de rip1k
CO2023008475A2 (es) Inhibidores de enzimas
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CL2022000217A1 (es) Inhibidores de enzimas
CL2004000705A1 (es) Sales cristalinas de compuestos derivados de n-formil-hidroxilamina, inhibidores de peptidil desformilasa (pdf); procedimiento de preparacion de las sales; composicion farmaceutica que las contiene; y su uso para tratar y/o prevenir un trastorno infe
AR126493A1 (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer